Guenther Dermatology Research Centre

52‐week ivarmacitinib in moderate‐to‐severe atopic dermatitis: A phase 3 trial

BACKGROUND: Ivarmacitinib, an oral JAK1 inhibitor, improved efficacy outcomes versus placebo at Week 16 in a phase 3 trial in patients with moderate-to-severe atopic dermatitis (AD). OBJECTIVES: To describe efficacy and safety outcomes through Week 52. METHODS: In this multicentr...

Constructive Organizational Geometry: From Configuration Structure to Transport, Connection, and Curvature

This paper develops the geometric layer of the Organizational Field Theory research program by examining how admissible organizational configurations can acquire a mathematically consistent geometric realization. Beginning with an organizational quotient rather than a preselected...